Comparative Pharmacology
Head-to-head clinical analysis: ANTARA MICRONIZED versus GEMFIBROZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTARA MICRONIZED versus GEMFIBROZIL.
ANTARA (MICRONIZED) vs GEMFIBROZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor alpha (PPARα). This leads to increased lipolysis and elimination of triglyceride-rich particles from plasma by inducing lipoprotein lipase activity and reducing production of apolipoprotein C-III.
Gemfibrozil is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and clearance of triglycerides from plasma, and reduced hepatic VLDL secretion. It also increases HDL cholesterol.
Oral: 130 mg once daily with or without food. Capsules should be swallowed whole; do not crush or chew.
Oral: 600 mg twice daily, 30 minutes before morning and evening meals.
None Documented
None Documented
Terminal elimination half-life is approximately 15–17 hours (range 13–22 hours) in normolipidemic subjects; in hypertriglyceridemic patients, half-life may be prolonged up to 24–33 hours due to increased volume of distribution. Repeated dosing leads to steady state by about 4–5 days.
Terminal elimination half-life is 1.5 hours. In patients with renal impairment, half-life may be prolonged up to 7-8 hours.
Renal (approximately 70% of a dose is excreted in the urine, primarily as the glucuronide conjugate; less than 10% is excreted as unchanged drug in urine); fecal/biliary elimination accounts for about 20% (mainly as unchanged drug and metabolites via bile).
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugate) with about 6% fecal elimination. Biliary excretion is minimal.
Category C
Category D/X
Fibrate
Fibrate